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Chronic and neuropathic pain constitute signiﬁcant health problems affecting millions of
individuals each year. Pain sensations typically originate in sensory neurons of the peripheral
nervous system which relay information to the central nervous system (CNS). Pathological
pain sensations can arise as result of changes in excitability of these peripheral sensory
neurons. Voltage-gated sodium channels are key determinants regulating action potential
generation and propagation; thus, changes in sodium channel function can have profound
effects on neuronal excitability and pain signaling. At present, most of the clinically avail-
able sodium channel blockers used to treat pain are non-selective across sodium channel
isoforms and can contribute to cardio-toxicity, motor impairments, and CNS side effects.
Numerous strides have been made over the last decade in an effort to develop more selec-
tive and efﬁcacious sodium channel blockers to treat pain. The purpose of this review is
to highlight some of the more recent developments put forth by research universities and
pharmaceutical companies alike in the pursuit of developingmore targeted sodium channel
therapies for the treatment of a variety of neuropathic pain conditions.
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INTRODUCTION
The International Association for the Study of Pain (ISAP) deﬁnes
pain as “an unpleasant sensory and emotional experience asso-
ciated with actual or potential tissue damage.” The ability to
experience painful stimuli is essential for an organism’s survival by
alerting the individual to engage in protective behaviors to prevent
further tissue damage or to seek appropriate actions to amelio-
rate the painful condition. Pain sensations typically originate in
nociceptors, peripheral nerve ﬁbers which transduce noxious ther-
mal, mechanical, or chemical stimuli into electrical impulses that
are then encoded via central pathways. The cell bodies of these
sensory nociceptors are located in the dorsal root ganglia (DRG)
with afferent projections to the dorsal horn of the spinal cord.
Persistent or chronic pain may linger beyond the initial acute
pain-producing stimulus and can become debilitating, severely
affecting an individual’s quality of life. It is estimated that in the
general population one out of ﬁve suffer from moderate or severe
chronic pain. Whereas certain types of persistent inﬂammatory
pain can be seen as an extension of the normal healing process,
neuropathic pain serves no known protective or healing purpose.
The ISAP deﬁnes neuropathic pain as “pain caused by a lesion or
disease of the somatosensory nervous system,” which can be sub-
divided into central and peripheral neuropathic pain. Common
types of neuropathic pain for which many people seek treat-
ment include post-herpetic neuralgia,painful diabetic neuropathy,
phantom limb pain, and spinal cord injury pain.
Neuropathic pain is typically characterized by allodynia (pain
produced by otherwise non-painful stimuli) and/or hyperalgesia
(exacerbated responses to painful stimuli). Neuropathic pain can
arise following an increase in intrinsic nerve excitability, gener-
ally manifested in impulses generated ectopically or with minimal
stimulation. DRG neurons express a wide variety of voltage-gated
sodium channels which regulate the excitability of these neurons
(Rush et al., 2007). Nerve injury can result in changes in sodium
channel trafﬁcking, gene expression, and/or channel kinetics, all of
which contribute to neuronalmembrane remodeling andhyperex-
citability associated with neuropathic pain (Devor, 2006). As such,
voltage-gated sodium channels are attractive targets for the devel-
opment of novel pain therapeutics. Currently used medications
for the treatment of neuropathic pain which have demonstrable
actions against sodium channels include tricyclic antidepressants
(TCAs: amitriptyline and nortriptyline), local anesthetics (lido-
caine, mexiletine), and anticonvulsants (carbamazepine, lamot-
rigine, phenytoin). However,most of the sodium channel blockers
that are currently available are often associatedwith cardio-toxicity
and central nervous system(CNS) side effects (Mulroy,2002;Walia
et al., 2004).
Several new strategies are emerging in the pursuit of providing
effective pain relief in patients exhibiting neuropathic pain while
minimizing adverse side effects typical of many currently available
medications. In this review, we will highlight (1) the development
of sodium channel blockers targeted at isoforms preferentially
expressed in peripheral sensory neurons involved in the initiation
and transductionof pain sensations, (2) techniques for limiting the
action of sodium channel blockers to the periphery, and (3) the
development of sodium channel modulators that target speciﬁc
patterns of sodium channel activity associated with problematic
pain.
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OVERVIEW OF VOLTAGE-GATED SODIUM CHANNELS
Voltage-gated sodium channels mediate the inward sodium cur-
rent of excitable cells and are thus key determinants regulat-
ing action potential generation and propagation (Hodgkin and
Huxley, 1952). Voltage-gated sodium channels can also inﬂu-
ence the resting potential of neurons and play critical roles in
setting the threshold for generation of action potentials (Rush
et al., 2007). Therefore, alterations in sodium channel function or
expression can have profound effects on normal cell excitability.
Sodium channels are dynamic transmembrane proteins consist-
ing of a pore-forming α-subunit (220–260 kDa) and auxiliary
β-subunits (32–36 kDa; Catterall, 2000). The α-subunit consists
of four homologous domains (I–IV), each consisting of six trans-
membrane α-helices (S1–S6). Additional loops join S5–S6 seg-
ments of each domain to form the outer mouth of the chan-
nel pore, with residues of the α-helical S6 segment forming the
inner mouth of the pore. The S1–S4 segments of each domain
serve as the voltage-sensor, with translocation of the positively
charged residues in the S4 segment initiating channel activation in
response to changes in the membrane potential. At resting mem-
brane potentials, the majority of the sodium channels are in the
closed conﬁguration,prohibiting sodium inﬂux.Upondepolariza-
tion, the channels proceed through multiple activation states with
translocation of all four S4 segments into the outward conﬁgu-
ration allowing sodium inﬂux. Within milliseconds, the channel
inactivates via a hinged-lid mechanism whereby a short cyto-
plasmic loop (which includes an isoleucine, phenylalanine and
methionine, IFM, motif) connecting domains III and IV folds
into the channel structure, occluding the pore (Vassilev et al.,
1988; West et al., 1992). Channel inactivation persists through-
out the depolarizing pulse, thus underlying the action potential
refractory period. Following hyperpolarization of the membrane
potential, the channel recovers from inactivation by returning to
the closed, resting state and is re-primed and available again for
activation. Perturbations in channel activation and inactivation
properties can modulate the onset, duration and frequency of
action potentials, thus affecting physiological neuronal signaling.
Todate,nineα-subunits (Nav1.1–1.9) and fourβ-subunits (β1–
4) have been identiﬁed in mammals (Goldin et al., 2000). Voltage-
gated sodium channel isoforms exhibit differential distribution
(Felts et al., 1997) as well as distinguishing electrophysiological
(Catterall et al., 2005; Rush et al., 2007) and pharmacological prop-
erties (England and De Groot, 2009). Seven of the nine isoforms
are neuronal,withNav1.4 andNav1.5 expressed in skeletal and car-
diacmuscle, respectively.Nav1.7,Nav1.8, andNav1.9 are expressed
almost exclusively in the peripheral nervous system (PNS). Most
of the sodium channel isoforms are sensitive to nanomolar con-
centrations of the puffer ﬁsh toxin, tetrodotoxin (TTX), while the
Nav1.5, Nav1.8, and Nav1.9 are resistant to TTX up to millimo-
lar concentrations. Table 1 summarizes some of the properties of
these channels.
Nav1.3, Nav1.7, Nav1.8, and Nav1.9 have been identiﬁed as
possible targets for analgesics. Nav1.3 and Nav1.7 are very sim-
ilar in structure to other neuronal sodium channels (Nav1.1,
Nav1.2, and Nav1.6) and the skeletal muscle sodium channel
(Nav1.4), but there are some interesting functional differences.
By contrast, Nav1.8 and Nav1.9 exhibit pronounced differences in
their sequences from other sodium channels (Goldin et al., 2000)
and striking functional differences. The next section provides
additional information on these four isoforms.
SODIUM CHANNEL ISOFORMS IMPLICATED IN ACQUIRED
AND INHERITED DISORDERS OF NEUROPATHIC PAIN
Nav1.7
TheNav1.7 isoform (originally PN1, hNE) encoded by the SCN9A
gene is expressed in the PNS, in both sensory and sympathetic
neurons as well as in Schwann cells and neuroendocrine cells
(Klugbauer et al., 1995; Felts et al., 1997; Sangameswaran et al.,
1997; Toledo-Aral et al., 1997). Nav1.7 is TTX-sensitive (TTX-
S) and like other TTX-S isoforms, it displays rapid activation
and inactivation kinetics. However, Nav1.7 does exhibit several
distinguishing characteristics with important functional effects
including a slow recovery from inactivation and a slow onset of
closed-state inactivation, resulting in the generation of promi-
nent ramp currents – inward currents generated during a slow,
depolarizing voltage ramp (Cummins et al., 1998; Herzog et al.,
2003). As such, neurons expressing Nav1.7 are capable of amplify-
ing slowly developing sub-threshold depolarizing inputs – such
as generator potentials arising in peripheral nociceptor termi-
nals – thereby directly modulating action potential threshold and
ultimately, neuronal excitability.
Recent clinical and experimental studies have implicated
Nav1.7 in playing a crucial role in inherited neuropathic pain
mechanisms. Speciﬁcally,mutations in SCN9A have been linked to
inherited pain syndromes (Figure 1). Mutations associated with
congenital insensitivity to pain (CIP) result in truncated, non-
functional Nav1.7 channels, and individuals unable to experience
pain (Cox et al., 2006). In contrast, inherited erythromelalgia
(IEM) and paroxysmal extreme pain disorder (PEPD) are distinct
severe pain syndromes associated with gain-of-function muta-
tions in SCN9A. IEM is characterized by episodes of burning
pain, erythema, and mild swelling in the hands and feet (Wax-
man and Dib-Hajj, 2005). PEPD is characterized by severe rectal,
ocular, and mandibular pain (Fertleman et al., 2007). Sensory
neurons expressing either IEM or PEPD mutant channels are
hyperexcitable, however, via distinct mechanisms (Rush et al.,
2006; Dib-Hajj et al., 2008). Whereas IEM mutations hyperpo-
larize the voltage-dependence of activation and slow the rate of
deactivation (Cummins et al., 2004; Dib-Hajj et al., 2005; Choi
et al., 2006; Theile et al., 2011), PEPD mutations destabilize fast
inactivation via a depolarizing shift in steady-state fast inactiva-
tion, slowed rate of open-channel fast inactivation and produce
persistent currents (Fertleman et al., 2006; Dib-Hajj et al., 2008;
Jarecki et al., 2008; Theile et al., 2011). PEPD mutant channels,
likely due to destabilized inactivation, also enhance resurgent
sodium currents (Jarecki et al., 2010; Theile et al., 2011), which
have beendemonstrated to facilitate high-frequencyﬁring (Raman
and Bean, 1997; Khaliq et al., 2003; Castelli et al., 2007) and
as such, may contribute to increased neuronal excitability and
extremepain sensations associatedwithPEPD(Jarecki et al.,2010).
Interestingly, a mutation in Nav1.7 was described in a patient
with clinical characteristics of both IEM and PEPD. This muta-
tion has biophysical characteristics common to both IEM and
PEPD mutations, suggesting that these disorders may be part of
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Table 1 | Summary of mammalian voltage-gated sodium channels.
Nav isoform Tissue expression Unique biophysical characteristics in DRG neurons TTX sensitivity,
kinetics
Role in pain
Nav1.1 CNS, PNS TTX-S, fast
Nav1.2 CNS, embryonic PNS Depolarized voltage-dependence TTX-S, fast
Nav1.3 CNS, embryonic PNS Rapid repriming; ramp currents; persistent currents TTX-S, fast Neuropathic; inﬂammatory
Nav1.4 Skeletal muscle TTX-S, fast
Nav1.5 Cardiac muscle TTX-R, fast
Nav1.6 CNS, PNS Rapid repriming; resurgent currents TTX-S, fast
Nav1.7 PNS Slow-repriming; slow closed-state inactivation; ramp
currents
TTX-S, fast Neuropathic; inﬂammatory;
hereditary
Nav1.8 PNS Depolarized voltage-dependence; rapid repriming;
majority of AP upstroke
TTX-R, slow Neuropathic; inﬂammatory
Nav1.9 PNS Persistent currents; hyperpolarized voltage-
dependence; window currents
TTX-R, very slow Inﬂammatory
FIGURE 1 | Nav1.7 mutations associated with inherited pain syndromes.
A linear representation of the Nav1.7 α-subunit showing the approximate
mutation sites for CIP, congenital insensitivity to pain; IEM, inherited
erythromelalgia; PEPD, paroxysmal extreme pain disorder.
a physiological continuum (Estacion et al., 2008). Furthermore, a
single nucleotide polymorphism in the SCN9A (rs6746030 in the
Single Nucleotide Polymorphisms database), is associated with
increased pain perception in patients with osteoarthritis, sciat-
ica, and phantom limb pain (Reimann et al., 2010), although the
mechanism by which this polymorphismmight increase pain sen-
sations is not clear. Overall these studies indicate that alterations
inNav1.7 properties can profoundly impact pain sensitivity. Based
on these ﬁndings, it has been proposed that Nav1.7 is also likely to
play important roles in the more common acquired neuropathic
pain syndromes.
Nav1.8
The Nav1.8 isoform (originally PN3, SNS), encoded by the
SCN10A gene, is expressed in nociceptive trigeminal and DRG
neurons (Akopian et al., 1996;Djouhri et al., 2003;Ho andO’leary,
2011). Nav1.8 is TTX-resistant (TTX-R), with an IC50> 50μM
when expressed in Xenopus oocytes (Akopian et al., 1996;
Sangameswaran et al., 1996). Early pharmacological characteri-
zation of Nav1.8 was limited due to its poor expression in sev-
eral mammalian heterologous expression systems, although func-
tional expression has been demonstrated in an immortalized rat
DRG/mouse neuroblastoma hybridoma cell line, ND7–23 (John
et al., 2004). DRG neurons express a second TTX-R isoform,
Nav1.9 (Cummins et al., 1999). Due to differences in voltage-
dependent properties and kinetics of Nav1.8 and Nav1.9, imple-
mentation of speciﬁc voltage-clamp protocols can allow for near
complete isolation of either current in DRG neurons (Dib-Hajj
et al., 1999; Priest et al., 2005; Sheets et al., 2008). In contrast to
the fast and rapidly inactivating TTX-S channels, Nav1.8 chan-
nels exhibit ∼10-fold slower kinetics with a depolarized voltage-
dependence of activation and inactivation (Akopian et al., 1996;
Cummins and Waxman, 1997). Reported values for kinetics and
voltage-dependent properties of Nav1.8 vary depending on anum-
ber of factors including: (1) cell background (John et al., 2004),
(2) channel ortholog (Browne et al., 2009), splice variants (Kerr
et al., 2004), and (3) possible contaminating expression of Nav1.9
currents. All of these factors can have an important impact on
drug discovery, and must be taken into careful consideration.
Nav1.8 channel-mediated currents are important determi-
nants in sensory neuron excitability and pain signaling. Studies
using Nav1.8-null mice have demonstrated that Nav1.8 carries the
majority of current underlying the upstroke of the action poten-
tial in nociceptive neurons (Renganathan et al., 2001). The use
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of Nav1.8 knock-out mice and antisense oligodeoxynucleotide
Nav1.8 knockdown have demonstrated a role for Nav1.8 in vis-
ceral and inﬂammatory pain (Akopian et al., 1999; Joshi et al.,
2006). However, whether Nav1.8 plays any role in neuropathic
pain is still a matter for debate (Kerr et al., 2001; Decosterd
et al., 2002; Nassar et al., 2005; Siqueira et al., 2009; Leo et al.,
2010). There are several lines of evidence that suggest some role
of Nav1.8 in certain models of neuropathic pain. Increased lev-
els of TNF-α in the cerebrospinal ﬂuid and in DRG tissue fol-
lowing L5 ventral root transection results in the upregulation
of Nav1.8 channel mRNA and protein levels (He et al., 2010).
TNF-α mediated increase in Nav1.8 current density increases
neuronal excitability, likely contributing to increased mechani-
cal allodynia following motor nerve injury (Chen et al., 2011).
Following sciatic nerve entrapment (SNE), a peripheral nerve
injury model similar to that of the chronic constriction injury
(CCI) model, upregulation of Nav1.8 mRNA is observed in sciatic
nerve axons which may underlie the observed increase excitabil-
ity as recorded from both A- and C-ﬁbers (Thakor et al., 2009).
However, in the SNE injury model, a concomitant decrease is
observed in Nav1.8 in L4–L5 DRG neuron cell bodies, suggest-
ing that the increased levels of mRNA may have occurred as a
result of translocation from the cell bodies. Similar changes in
Nav1.8 protein have been observed following CCI (Novakovic
et al., 1998). As will be discussed below, several Nav1.8-selective
inhibitors have been shown to be analgesic in several neuropathic
pain animal models.
Nav1.3
The TTX-S isoform Nav1.3 is the predominant sodium channel
isoform expressed in the CNS and PNS during embryogene-
sis, with very low levels in the PNS in adults (Waxman et al.,
1994). However, Nav1.3 levels increase in the periphery follow-
ing nerve injury and inﬂammation, suggesting that this channel
could play a role in pain (Black et al., 2004). Nav1.3 levels are
also increased in the dorsal horn following SCI (Lampert et al.,
2006) and in DRG neurons following motor ﬁber injury (He
et al., 2010). In addition, patients with trigeminal neuralgia, a
disorder characterized by ectopic action potentials in trigemi-
nal neurons, exhibit increased expression of Nav1.3 in gingival
tissue (Siqueira et al., 2009). Nav1.3 channels exhibit fast kinet-
ics with rapid recovery from inactivation, poising these chan-
nels to contribute to pathological high-frequency ﬁring following
nerve injury (Cummins and Waxman, 1997), although Nav1.3
knock-out animals still exhibit normal neuropathic pain behav-
ior and ectopic discharges from damaged nerves (Nassar et al.,
2006).
Nav1.9
Nav1.9-mediated TTX-R sodium currents are extraordinarily
slow persistent currents with a relatively hyperpolarized voltage-
dependency compared to the other isoforms (Cummins et al.,
1999). Due to the slow, persistent nature of Nav1.9 currents
these channels likely do not contribute to the upstroke of the
action potential, though they may amplify sub-threshold depo-
larizations and lower the threshold for action potential induction
(Cummins et al., 1999; Herzog et al., 2001; Baker et al., 2003).
Studies using Nav1.9 KO mice suggest that this peripheral iso-
form plays a predominant role in inﬂammatory pain but not
neuropathic pain (Priest et al., 2005; Amaya et al., 2006). How-
ever, even the role in inﬂammatory pain is somewhat unclear as
antisense oligodeoxynucleotide-mediated knockdown of Nav1.9
does not reduce thermal hypersensitivity associated with com-
plete Freund’s adjuvant (CFA)-induced inﬂammatory pain (Yu
et al., 2011). Although Nav1.9 currents are downregulated fol-
lowing nerve injury (Cummins and Waxman, 1997; Decosterd
et al., 2002), in an L5 spinal nerve ligation model of neuropa-
thy reduction of Nav1.9 mRNA expression is minimal in animals
that exhibited themost pain andmaximal in animalswithminimal
pain (Persson et al., 2009), suggesting that Nav1.9 may play a role
in determining pain threshold. As Nav1.9 expression is restricted
to the PNS, Nav1.9 is an attractive target for modulating pain
sensitivity.
DEVELOPMENT OF DRUGS FOR NOCICEPTOR-SELECTIVE
BLOCKADE
Nav1.7-SELECTIVE INHIBITORS
Given the role of Nav1.7 in pain and its expression limited to
the periphery, it has been proposed that drugs selectively target-
ing Nav1.7 may be ideal analgesics. Despite the uncertain role
of Nav1.7 in acquired neuropathic pain disorders (see above),
recently developed Nav1.7-selective blockers have been shown
to be efﬁcacious in rat models of neuropathic pain. Researchers
at Merck, using benzodiazepine as a molecular building block,
developed a series of structurally novel benzazepinone-based
state-dependent selective hNav1.7 blockers that displayed nearly
complete inhibition of spontaneous neuronal ﬁring in vivo in a
rat peripheral axotomy model and reversed tactile allodynia in
a rat model of spinal nerve ligation (SNL; Hoyt et al., 2007a).
Following up on that study, two additional related compounds
were developedwith improved oral bioavailability andwere highly
efﬁcacious in a rat model of SNL, with comparable or increased
efﬁcacy compared to the clinical standard, mexiletine (Hoyt et al.,
2007b). However, these benzazepinone-based Nav1.7 blockers
exhibited less than ideal pharmacokinetics (PK) with high clear-
ance rates, thus Merck Research Laboratories developed a series of
imidazopyridine-based blockers with improved PK and excellent
efﬁcacy in a rat SNL model with an associated reversal of inﬂam-
matory pain (London et al., 2008). Additional Nav1.7-selective
compounds developed byMerck include the biphenyl thiazole car-
boxamides (Tyagarajan et al., 2010a) and biphenyl pyrazoles (Tya-
garajan et al., 2010b,c). ProTx-II from the tarantula Thrixopelma
prurient has also been reported to inhibit Nav1.7 by inducing
a depolarizing shift in the voltage-dependence of activation and
displays about 100-fold selectivity over the other Nav isoforms
(Schmalhofer et al., 2008). Interestingly, ProTx-II seems to tar-
get the voltage-sensors of Nav isoforms (Schmalhofer et al., 2008;
Xiao et al., 2010), suggesting that drugs targeting speciﬁc voltage-
sensors of Nav1.7 may exhibit enhanced isoform selectivity. How-
ever, the therapeutic utility of ProTx-II in vivo may be limited by
its nanomolar afﬁnity to the other Nav isoforms and the ineffec-
tiveness in reducing short-term or inﬂammatory pain following
intravenous or intrathecal delivery, possibly related to its inability
to cross the blood–nerve barrier (Schmalhofer et al., 2008).Amgen,
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Inc., has recently reported on a state-dependent Nav1.7 inhibitor
which displays efﬁcacy in a formalin model of pain in rodents,
although this compound displays only modest selectivity for
Nav1.7 compared to Nav1.5 and Nav1.8 (Bregman et al., 2011).
Interestingly, the binding site of this compound does not appear
to overlap the local anesthetic binding site, as displacement of
bound tritiated batrachotoxin (3H-BTX) is not observed. Addi-
tionally, Xenon Pharmaceuticals currently has a Nav1.7-selective
compound (XEN402) in the form of a topical ointment for the
treatment of post-herpetic neuralgia in Phase II clinical trials.
Nav1.8-SELECTIVE INHIBITORS
Although early studies using Nav1.8 knock-out mice suggested a
lack of a role of Nav1.8 in the development of neuropathic pain
(Akopian et al., 1999; Nassar et al., 2005), the discovery of the μO-
conotoxin MrVIB and the small molecule A-803476, both potent
and selective Nav1.8 inhibitors demonstrating efﬁcacy in atten-
uating neuropathic pain in rats, fueled interest in the search for
selective Nav1.8 inhibitors for the treatment of neuropathic pain.
MrVIB inhibition of sodium channels is not voltage-dependent
and has only 10-fold higher selectivity for Nav1.8 over TTX-S
currents in DRG neurons (Ekberg et al., 2006). While exhibit-
ing 100-fold selectivity of Nav1.8 over Nav1.9, MrVIB inhibits
Nav1.4 channels almost equally well as Nav1.8, potentially limit-
ing the therapeutic effectiveness of MrVIB. In contrast, A-803467
reportedly exhibits>100-fold selectivity for both resting and inac-
tivated hNav1.8 channels over hNav1.2, hNav1.3, hNav1.5, and
hNav1.7 channels expressed inHEK293 cells (Jarvis et al., 2007).A-
803467 has demonstrated 10-fold greater selectivity for inactivated
Nav1.8 compared to the anticonvulsant compound V102862 and
100- to 1000-fold greater selectivity compared to the local anes-
thetic tetracaine, the α-amino amide derivative ralﬁnamide, and
the lamotrigine derivative 227c89 (Browne et al., 2009). Systemic
administration of A-803467 demonstrated acute antinociceptive
activity as measured as a reduction in mechanical allodynia in
several models of inﬂammatory and neuropathic pain in rats
(Jarvis et al., 2007). Additionally, systemic and intraspinal deliv-
ery of A-803467 attenuates both evoked and spontaneous ﬁring
of wide dynamic range neurons in rats with spinal nerve ligations
(Mcgaraughty et al., 2008). Following the discovery of A-803467, a
series of structurally related compounds have been developed also
exhibiting low nanomolar IC50 for Nav1.8 (Kort et al., 2008, 2010;
Scanio et al., 2010).
More recently, scientists atAbbott Laboratories and Icagen, Inc.,
collaborated on the development of an additional Nav1.8-selective
blocker, A-887826 (Zhang et al., 2010). A-887826 is structurally
distinct from A-803467, and displays enhanced potency toward
Nav1.8. At a holding potential of −40mV, A-887826 blocks TTX-
R currents in small diameter DRG neurons with an IC50 of 8 nM,
compared toA-803467 with an IC50 of 140 nM (Jarvis et al., 2007).
Although A-887826 displays greater potency for Nav1.8 compared
to A-803467, its selectivity to other channels is reduced (3-fold,
30-fold, and 28-fold more potent for Nav1.8 compared to Nav1.2,
Nav1.5, andNav1.7 respectively).Oral administrationof A-887826
dose-dependently attenuates tactile allodynia in a spinal nerve
ligation model of neuropathic pain (Zhang et al., 2010). Both
compounds attenuated evoked action potential ﬁring in neurons
clamped at −40mV and suppressed spontaneous ﬁring induced
2 days following CFA-induced inﬂammation. Interestingly, unlike
most sodium channel blockers, both compounds demonstrate
high nanomolar afﬁnity for block of resting channels and neither
compound displays frequency-dependent inhibition of Nav1.8,
thus suggesting that themechanism of alleviatingmechanical allo-
dynia likely does not involve selective inhibition of high-frequency
ﬁring neurons due to progressive block of Nav1.8, as is the case of
typical anticonvulsant sodium channel blockers.
For both A-803467 and A-887826, there were considerable
differences in IC50 values for different TTX-R currents, with
hNav1.8< rNav1.8< native TTX-R currents in DRG neurons,
suggesting that subtle differences in either channel sequence or
in cell background can affect the drug/channel interaction. Pur-
suant to this, hNav1.8 and rNav1.8 channels display signiﬁcant
differences in the voltage-dependence of steady-state fast inactiva-
tion when both channels are expressed in ND7–23 cells (Browne
et al., 2009). Furthermore, in that report, the half-inactivation
for human (∼−80mV) and rat (∼−64mV) Nav1.8 channels
expressed in ND7–23 cells are signiﬁcantly hyperpolarized com-
pared to other reports for Nav1.8 in Xenopus oocytes (∼−30mV;
Akopian et al., 1999), DRG neurons (∼−30mV; Cummins and
Waxman, 1997; Sheets et al., 2008), and HEK293 cells (∼−50mV;
Jarvis et al., 2007). Collectively, these reports underscore the
importance of considering both the cell background and channel
ortholog used in the drug development process. Additionally, due
to the state-dependent binding characteristics of many of the small
molecule Nav1.8 sodium channel blockers, careful consideration
must be used in the design of voltage-protocols, as the membrane
holding potential can inﬂuence both the half-inactivation poten-
tial as well as the relative drug binding afﬁnity (John et al., 2004;
Browne et al., 2009). Despite initial excitement regarding the abil-
ity of A-803467 tomodulate pain sensations (Rush and Cummins,
2007), its usefulness as a research tool has been limited by these
and other factors.
Ambroxol, a secretolytic used predominantly in the treatment
of respiratory disorders and as a cough suppressant, inhibits both
TTX-S and TTX-R sodium currents, although with a slightly
higher potency for TTX-R channels (Weiser and Wilson, 2002).
Ambroxol shares an overlapping binding site with local anesthet-
ics and exhibits preferential use-dependent block, but not tonic
block, for Nav1.8 (Lefﬂer et al., 2010). Although weakly effective
in acute pain models, ambroxol reducedmechanical allodynia in a
partial nerve ligation (PNL) model and reduced thermal hyperal-
gesia, cold allodynia, and mechanical hyperalgesia in a CCI model
(Gaida et al., 2005). Oral administration of ambroxol reversed
below-injury level tactile and noxious heat hypersensitivity in SCI
rats (Hama et al., 2010).
Nav1.3 AND Nav1.9-SELECTIVE INHIBITORS
Although Nav1.3 channels have been implicated in pain mecha-
nisms (Hains et al., 2003; Siqueira et al., 2009), Nav1.3 speciﬁc
blockers have not been identiﬁed. Nav1.3 is highly homologous to
other sodium channels. For example, Nav1.2 and Nav1.3 are more
than 85% identical. This likely limits the probability that Nav1.3
selective blockers can be developed (Catterall et al., 2005). In con-
trast,Nav1.9 is only about 45% identical to the other voltage-gated
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sodium channel isoforms. However, it has been difﬁcult to iden-
tify chemicals that modify Nav1.9 currents because Nav1.9 has
proven very difﬁcult to express in heterologous systems and typi-
cally exhibits rapid run-down inDRGneurons (Lefﬂer et al., 2005).
Recently a clever approach has been employed to help identify tox-
ins that interact with Nav1.9 channels (Bosmans et al., 2011). In
this study, individual voltage-sensor paddles of Nav1.9 were trans-
planted into potassium channel constructs and these chimeric
constructs were used to screen for toxins that might target full-
length Nav1.9 channels. Although this study indicated that Nav1.9
channels havedistinctive pharmacological sensitivities and that the
voltage-sensor paddles of Nav1.9 might be excellent targets, it is
unclear to what extent the chimeric channels faithfully reproduce
the pharmacological properties of the full-lengthNav1.9 channels.
TECHNIQUES FOR LIMITING THE ACTION OF SODIUM
CHANNEL BLOCKERS TO THE PERIPHERY
COMBINATIONAL THERAPY: TRPV1 AGONISTS AND LOCAL
ANESTHETICS
Local anesthetics such as lidocaine block nociceptive nerve trans-
mission via inhibition of sodium channels and are thus clinically
useful for the treatment of pain. Local anesthetics are lipophilic in
their uncharged form and gain access to the intracellular sodium
channel pore binding site by diffusion across cell membranes.
However, local anesthetics are non-selective across sodium chan-
nel isoforms causing block of cardiac sodium channels as well as
non-nociceptive sensory, sympathetic and motor ﬁbers leading to
adverse and potentially toxic side effects. Thus, development of
localized anesthesia via selective inhibition of nociceptive ﬁbers
would greatly enhance the clinical utility of local anesthetics in
treating pain.
A novel strategy for such an approach was recently developed
that exploited the relatively selective expression of the transient
receptor potential vanilloid 1 (TRPV1) receptor to nociceptive
sensory neurons (Binshtok et al., 2007). TRP channels are key reg-
ulators of sensory transduction (Patapoutian et al., 2009). Specif-
ically, TRPV1 channels are polymodal nocitransducers activated
by noxious stimuli including high heat (>43˚C), low pH (<6.0)
and the pungent ingredient of chili peppers, capsaicin (Caterina
et al., 1997; Tominaga et al., 1998). TRPV1 channels have large
pores capable of passing small charged molecules, such as QX-
314, a permanently charged quaternary derivative of lidocaine.
Normally, QX-314 has no effect on neuronal sodium channels
when applied extracellularly but does induce block when applied
intracellularly (Figure 2). Following activation of TRPV1 via cap-
saicin,Woolf and colleagues utilized the large pore of TRPV1 as a
conduit by which to deliver QX-314 into the cell interior in order
to block Na+ currents in DRG neurons (Binshtok et al., 2007).
Furthermore, because TRPV1 channels are restricted primarily to
nociceptive neurons, co-injection of capsaicin and QX-314 into
the rat hindpaw or near the sciatic nerve produced a long-lasting
decrease in pain sensitivity without any motor or tactile deﬁcits.
However, the use of capsaicin as a TRPV1 agonist presents an
obvious downside for pain relief in that capsaicin itself produces
acute pain upon application prior to the slowly developingQX-314
mediated block of nociceptive transmission. Interestingly, pre-
treating withQX-314 prior to capsaicin injection imparted little or
FIGURE 2 |Transient receptor potential vanilloid 1 and QX-314: No
pain, no gain. Due to its positive charge, the lidocaine derivative QX-314 is
unable to pass through the plasma membrane to gain access to its binding
site on the intracellular face of the sodium channel pore. Activation of
TRPV1 by capsaicin (the pungent ingredient in chili peppers) allows QX-314
to pass through the relatively large pore of TRPV1, shuttling QX-314 into the
cytosol where it can bind and inhibit the sodium channel. TRPV1 receptors
are preferentially expressed on nociceptive terminals thus allowing
selective inhibition of pain-transmitting nerve ﬁbers.
no response to capsaicin, possibly due to the immediate entry of
QX-314 already in the extracellular space following activation of
TRPV1, or inhibition of TRPV1 channels by low concentrations
of QX-314 (Rivera-Acevedo et al., 2011). Although the use of a
non-pungent TRPV1 agonist, such as eugenol (Yang et al., 2003)
would circumvent the irritating aspect of capsaicin, formulation
issues have so far prevented successful co-application of eugenol
and QX-314 in vivo (Roberson et al., 2011). It should be noted
that intrathecal administration of QX-314 in mice can be lethal,
suggesting that QX-314 should be avoided for spinal anesthesia in
humans (Schwarz et al., 2010).
Interestingly, lidocaine itself is an activator of TRPV1 channels,
although only at a concentration sufﬁcient to produce appreciable
block of sodium channels (Lefﬂer et al., 2008). Nonetheless, co-
application of lidocaine and QX-314 produces a long-lasting dif-
ferential nerve block (with nociceptive block far outlasting motor
block) better than lidocaine alone (Binshtok et al., 2009), without
the initial irritation induced by capsaicin administration. Follow-
ing pre-treatment with an amphipathic quaternary ammonium
sodium channel blocker (N -methyl amitriptyline) and tertiary
amine sodium channel blockers (amitriptyline, bupivacaine, and
lidocaine), injection of capsaicin near the rat sciatic nerve results
in long-lasting differential nerve block with the more hydropho-
bic drugs producing the largest differential block (Gerner et al.,
2008). In an effort to determine the optimal concentration and
ratio of lidocaine and QX-314 resulting in long-lasting dura-
tion of nociceptive-selective differential nerve block, Woolf and
colleagues recently underwent a systematic study exploring mul-
tiple combinations of drug doses in a rat sciatic nerve model
(Roberson et al., 2011). The authors determined that the com-
bination of 0.5% QX-314 and 2% lidocaine administered near
the sciatic nerve produced 1 h of non-selective sensory and motor
block followed by >9 h of pain selective block. Though initially
counter-intuitive (causing pain in order to alleviate pain), the
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use of TRPV1 as a drug delivery portal represents an ingenious
new platform for future researchers to build upon in the pos-
sible development of membrane-impermeable, subtype-selective
sodium channel blockers that can be delivered to pain sensing
terminals.
DEVELOPMENT OF SODIUM CHANNEL BLOCKERS THAT DO NOT CROSS
THE BLOOD BRAIN BARRIER
Due to the restricted expression of Nav1.7, Nav1.8, and Nav1.9 to
the periphery, development of poorly brain-penetrant Nav selec-
tive compounds may increase tolerability due to reduced actions
on CNS Nav isoforms. Indeed, a small molecule Nav1.7 inhibitor
developed by Merck, N-[(R)-1-((R)-7-chloro-1-isopropyl-2-oxo-
2,3,4,5-tetrahydro-1H-benzo[b]aze pin-3-ylcarbamoyl)-2-(2-ﬂu-
orophenyl)-ethyl]-4-ﬂuoro-2-triﬂuoromethyl-benzamide (BZP),
produces substantial reversal of inﬂammatory hyperalgesia and
mechanical allodynia comparable to that of standard clinical
drugs, but due to its poor brain-penetrance, BZP conferred fewer
sedative, and motor-coordination impairments (Mcgowan et al.,
2009). Although sodium channel blockers that do not penetrate
the BBB may help reduce CNS associated side effects, actions
against cardiac sodium channels could still be problematic, as
could the use of such compounds in conditions which compro-
mise the BBB (e.g., certain spinal cord injuries) or the blood-spinal
cord barrier (Beggs et al., 2010).
TARGETING SODIUM CHANNEL ACTIVITY RATHER THAN THE
ISOFORM
As detailed above, isoform-speciﬁc sodium channel blockers that
are targeted at isoforms preferentially expressed in the peripheral
sensory neurons (Nav1.7, Nav1.8, and Nav1.9) may be very effec-
tive at treating pain while minimizing signiﬁcant side effects. An
alternative approach is to identify sodiumchannelmodulators that
target speciﬁc patterns of sodium channel activity that are associ-
ated with problematic pain. Below we highlight several properties
of sodium channel function which have shown to be promising
pain targets.
SLOW-INACTIVATION
Within milliseconds following activation sodium channels enter
a non-conducting fast-inactivated state; accounting for the action
potential refractory period until the membrane potential has been
sufﬁciently repolarized allowing the channels to become avail-
able again for activation. However, under conditions of prolonged
(within seconds to minutes) depolarizations, sodium channels
can also enter a slow-inactivated state (Figure 3). Whereas the
mechanism of fast inactivation entails occlusion of the pore by
translocation of the IFM motif of the DIII–DIV intracellular
linker, the mechanism of slow-inactivation is believed to be due
to structural rearrangement of the pore (Goldin, 2003). In neu-
ropathic pain, sensory neurons become hyperexcitable, eliciting
repetitive action potentials resulting in a progressively depolar-
ized membrane potential. These sustained depolarizations reduce
sodium channel availability as a result of accumulation into the
slow-inactivated state, dampening neuronal excitability. As typi-
cal anticonvulsants curtail pathological high-frequency ﬁring by
preferentially binding open/inactivated channels, small molecules
FIGURE 3 | Lacosamide enhances sodium channel slow-inactivation
without altering fast inactivation. (A) Carbamazepine, but not
lacosamide, enhances Nav1.7 fast inactivation as evident by a
hyperpolarizing shift in the voltage-dependence of steady-state fast
inactivation. (B) Lacosamide, but not carbamazepine, causes a signiﬁcant
shift in the voltage-dependence of Nav1.7 slow-inactivation. (C,E) Pulse
protocols for determining the voltage-dependence of fast and
slow-inactivation, respectively. (D) A simpliﬁed diagram showing the
different channel occupancy states, where C indicates the closed-state, O
the open state, FI the fast-inactivated state and SI the slow-inactivated
state. (A,B) adapted from Sheets et al. (2008) with permission fromThe
Journal of Pharmacology and Experimental Therapeutics.
capable of stabilizing channels into the slow-inactivated state may
represent an additional therapeutic approach for selectively target-
ing hyperexcitable neurons while sparing normal, low-frequency
spiking activity.
Lacosamide is a functionalized amino acid that was synthe-
sized during the development of anticonvulsant drug candidates
and has displayed antinociceptive properties in inﬂammatory and
neuropathic pain (Beyreuther et al., 2006; Hao et al., 2006; Stohr
et al., 2006; Bee and Dickenson, 2009; Wymer et al., 2009; Ziegler
et al., 2010). Lacosamide displays a unique mechanism of action
in that it seemingly selectively stabilizes channels into the slow-
inactivated state (Errington et al., 2008). In that study, lacosamide
had no apparent effect on fast inactivation of sodium channels
from neocortical neurons, nor did it exhibit rapid use-dependent
block which is typical of the prototypical anticonvulsants. In a
similar study, lacosamide inhibited currents from Nav1.3, Nav1.7,
and Nav1.8, but only after prolonged depolarizations, consistent
with an enhancement in slow-inactivation with no effect on fast
inactivation (Sheets et al., 2008). Furthermore, Sheets et al. (2008)
observed that lacosamide was better able to discriminate between
resting and inactivated channels compared to lidocaine or carba-
mazepine (Figure 3), thus likely allowing for improved selectivity
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over neurons with a depolarized membrane potential, with little
tonic block.
Recently, several other compounds have been identiﬁed that
also seem to selectively stabilize the slow-inactivated state
(Table 2). Structurally novel derivatives of lacosamide have been
developed that exhibit enhanced binding to the slow-inactivated
state compared to lacosamide (Wang et al., 2011). Brilliant Blue
G, also known as Coomassie blue, was recently demonstrated to
be a potent inhibitor of sodium channels with a much higher
afﬁnity for the slow-inactivated state compared to the fast-
inactivated state (Jo and Bean, 2011). Zalicus Pharmaceuticals
recently developed a small, organic compound, Z123212, which
selectively stabilizes slow-inactivation of recombinant Nav1.7,
Nav1.8, and Cav3.2 T-type currents, as well as TTX-S and TTX-
R currents from lamina I/II spinal cord neurons, with no effect
on the voltage-dependence of fast inactivation for sodium or
Cav3.2 currents (Hildebrand et al., 2011). In that study, Z123212
is considerably more potent (IC50 = 480 nM) than lacosamide
(IC50 = 150μM) in inhibiting AP ﬁring elicited in response to
a steady current injection. Furthermore, oral administration of
Z123212 at doses within the range to enhance slow-inactivation
resulted in a signiﬁcant reversal of tactile allodynia and thermal
hyperalgesia in SNL rats with no observable effects on motor-
coordination or cardiovascular properties. These studies suggest
that targeting slow-inactivation represents a potentially advanta-
geous approach for the targeting of pathologically depolarized
neurons associated with neuropathic pain. However, it should
be noted that it can be very difﬁcult to distinguish between
a compound that targets slow-inactivation and one that sim-
ply exhibits very slow binding and unbinding to fast-inactivated
channels. This caveat must be kept in mind when trying to
deﬁnitively determine a mechanism of action with inactivation
modiﬁers.
PERSISTENT SODIUM CURRENTS
Persistent sodium currents can arise when sodium channels fail
to fully inactivate after opening, resulting in a very small residual
sodium inﬂux, representing only a fraction of the transient cur-
rent (∼1%). Additionally, persistent currents can arise at voltages
in which channels are activated but inactivation is sub-maximal
(“window currents”). Persistent currents can play a critical role in
modulating both resting membrane potential and action poten-
tial threshold, thus modulating neuronal excitability. Increased
persistent currents have been observed under pathological condi-
tions of hyperexcitability and may be associated with neuropathic
pain. Nav1.7-PEPD mutations exhibited increased persistent cur-
rents (Jarecki et al., 2008; Theile et al., 2011), and inhibition of
these currents is a proposed mechanism by which carbamazepine
is effective in treating pain in PEPD patients (Fertleman et al.,
2006). Upregulation of Nav1.3-mediated persistent currents in
dorsal horn neurons is observed following contusive SCI in rats,
and likely contributes to neuronal hyperexcitability seen in these
neurons (Lampert et al., 2006). In rats, chronic constriction of
L5 dorsal root ganglion (CCD) results in mechanical allodynia
and increased persistent currents in injured A-type ﬁbers, both
of which are reduced by the persistent current-selective inhibitor,
riluzole (Xie et al., 2011).
Riluzole is a neuroprotective agent mainly used in the treat-
ment of amyotrophic lateral sclerosis (Bensimon et al., 1994),
however it also displays anticonvulsant and antiepileptic prop-
erties in animals models (Romettino et al., 1991; Zgrajka et al.,
2010). The neuroprotective properties of riluzole partially stem
from its actions to reduce pre-synaptic glutamate release and/or
via post-synaptic inhibition of NMDA receptors (Cheramy et al.,
1992; Debono et al., 1993). Riluzole also displays activity against
sodium channels, inhibiting TTX-S and TTX-R currents in DRG
neurons equally well in a state-dependent manner (Song et al.,
1997). In CNS and cardiac sodium channel isoforms, riluzole
at low concentrations selectively inhibits persistent sodium cur-
rents compared to transient currents (Urbani and Belluzzi, 2000;
Weiss et al., 2010). Recently, riluzole has demonstrated antinoci-
ceptive properties on below-level cutaneous hypersensitivity in
rats with spinal cord injury, although it is not clear if this
effect is mediated via sodium channel inhibition or a reduction
Table 2 | Summary of voltage-gated sodium channel blockers.
Compound Selectivity Likely mechanism of action References
Benzazepinone series Nav1.7>Nav1.5Nav1.8 State-dependent inhibition Hoyt et al. (2007a,b)
Pyrazole 20 Nav1.7>Nav1.8 State-dependent inhibition Tyagarajan et al. (2010)
ProTx-II Nav1.7Nav1.2-Nav1.6, Nav1.8 Voltage-sensor trapper Schmalhofer et al. (2008)
2,4-diaminotriazine 52 Nav1.7≈Nav1.3, Nav1.4>Nav1.5, Nav1.8 State-dependent inhibition Bregman et al. (2011)
MrVIB Nav1.8≈Nav1.4>Nav1.2, Nav1.3, Nav1.5,
Nav1.7Nav1.9
Blocks conduction pathway Ekberg et al. (2006), Zorn et al. (2006)
A-803467 Nav1.8Nav1.2, Nav1.3, Nav1.5, Nav1.7 State-dependent inhibition Jarvis et al. (2007)
Ambroxol Nav1.8≥TTX-S channels State-dependent inhibition Lefﬂer et al. (2010)
Capsaicin+QX-314 TRPV1 expressing neurons TRPV1 activation paired with
state-dependent inhibition
Binshtok et al. (2007)
Lacosamide Chronically depolarized channels Enhanced slow-inactivation Errington et al. (2008)
Z123212 Chronically depolarized channels Enhanced slow-inactivation Hildebrand et al. (2011)
Riluzole Persistent currents Enhanced fast inactivation Urbani and Belluzzi (2000)
Ranolazine Persistent currents Open-channel block Wang et al. (2008)
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in glutamatergic transmission (Hama and Sagen, 2011). The
authors also observed general antinociceptive effects of riluzole on
uninjured rats when administered peripherally but not centrally.
Because persistent sodium currents, especially those that occur at
or near the threshold for action potential generation, can substan-
tially increase excitability, drugs that selectively target persistent
currents in nociceptive neurons could be very useful in treating
pain.
The analgesic potential of ranolazine, a drug that is FDA
approved for treatment of chronic angina pectoris, has been inves-
tigated because ranolazine preferentially inhibits persistent cardiac
sodium currents as well as sensory neuronal sodium channels
(Rajamani et al., 2008,2009;Wang et al., 2008). Ranolazine inhibits
sensory neuronal excitability and the behavioral signs of inﬂam-
matory andneuropathic pain (Gould et al., 2009;Casey et al., 2010;
Estacion et al., 2010). Although targeting persistent sodium cur-
rents in sensory neurons may be efﬁcacious in treating pain, both
riluzole and ranolazine interact with a broad spectrum of sodium
channels, including cardiac and CNS channels, which may not be
ideal.
RESURGENT SODIUM CURRENTS
Recently it has been proposed that resurgent sodium currents
might also contribute to enhanced pain sensitivity (Jarecki et al.,
2010). After opening, Nav channels normally undergo inactiva-
tion within milliseconds via occlusion of the pore with the IMF
inactivation particle. Channels are refractory following inacti-
vation until the membrane has been hyperpolarized to resting
potentials, repriming the channel. Under certain conditions chan-
nels can re-open during repolarization to moderately negative
potentials allowing a surge of inward current (resurgent cur-
rent; Figure 4). Resurgent sodium currents were ﬁrst identiﬁed
in cerebellar Purkinje neurons (Raman and Bean, 1997) and more
recently in DRG neurons (Cummins et al., 2005). These currents
are proposed to ﬂow following relief of ultra-fast open-channel
block by an endogenous cytosolic blocking particle, proposed to
be the C-terminal tail of the auxiliary Navβ4 subunit (Grieco
et al., 2005; Bant and Raman, 2010). Resurgent currents facil-
itate recovery from inactivation and are maximal at potentials
near the action potential threshold, and as such, may contribute
to high-frequency ﬁring (Raman and Bean, 1997; Khaliq et al.,
2003; Castelli et al., 2007). Although Nav1.6 is the predominant
carrier of resurgent current in DRG neurons (Cummins et al.,
2005), other isoforms can carry this current under pathological
conditions of impaired inactivation (Grieco and Raman, 2004;
Jarecki et al., 2010). Furthermore, enhanced resurgent currents
are associated with the Nav1.7-PEPD mutations (Jarecki et al.,
2010; Theile et al., 2011). Thus, resurgent currents potentially
represent a novel drug target for the treatment of pain. As
resurgent currents arise following transition to a unique chan-
nel state (open-channel block), it may be possible to develop
small molecules capable of selectively targeting resurgent cur-
rents. Indeed, a recent study showed that anandamide is able
to inhibit resurgent sodium currents at concentrations that have
little impact on peak transient currents (Theile and Cummins,
2011).
FIGURE 4 | Resurgent sodium currents. (A) Following a strong
depolarization, sodium channels transition from the resting closed-state to
open, allowing inﬂux of sodium.Within milliseconds, the channel inactivates
via a hinged-lid mechanism and remains inactivated until the membrane
potential has been sufﬁciently hyperpolarized. This cycle of events underlies
the action potential refractory period. (B) Following a strong depolarization, a
blocking particle (likely the C-terminal portion of the auxiliary Navβ4 subunit)
can occlude the open-channel before the inactivation gate can bind, thus
resulting in open-channel block. Following a hyperpolarization to an
intermediate potential, the blocker is expelled resulting in an additional surge
in current. (C) Representative resurgent sodium currents recorded from a
large Nav1.8-null DRG neuron. The traces are magniﬁed in the right panel to
better see the resurgent currents. (D)The voltage-dependence of the
resurgent currents is shown by plotting the peak resurgent current amplitude
against the repolarization pulse potential. (C,D) adapted from Cummins et al.
(2005) with permission from FEBS Letters.
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CONCLUSION
Voltage-gated sodium channels are emerging as exciting targets
for the treatment of neuropathic pain, albeit several challenges
must be overcome. The currently available sodium channel block-
ers used for treatment are non-speciﬁc among sodium channel
subtypes, resulting in undesirable side effects thus limiting their
clinical utility. However, as highlighted in this review, researchers
have made considerable advances in the pursuit of developing
sodiumchannel blockerswith improved efﬁcacywhileminimizing
off-target effects. Several pharmaceutical companies are engaged
in the development of subtype-selective blockers targeted to the
peripheral neuronal isoforms Nav1.7 and Nav1.8, which have
a demonstrable role in pain mechanisms. In fact, several such
blockers have entered into human clinical trials. Other exciting
new approaches involve techniques limiting drug delivery to the
periphery via the development of brain-impenetrable blockers and
a unique approach that exploits the TRPV1 receptor. Additionally,
as the widely used anticonvulsants antagonize aberrant sodium
channel activity due to their state-dependence, identifying, and
developing other state-dependent drugs which target pathological
sodium channel activity may circumvent the challenges associated
with developing drugs targeting the subtle differences between
the highly homologous channel isoforms. Furthermore, resurgent
current generation relies on the presence of the accessory Navβ4
protein. As resurgent currentsmay play a role in pathological pain,
drugs targeting Navβ4 or other accessory proteins associated with
sodium channels may represent yet another avenue for pain ther-
apy. Overall, recent advances in our knowledge of sodium channel
properties and increased understanding of the roles that speciﬁc
isoforms play in abnormal pain syndromes makes this an exciting
time for novel pain therapeutics that target voltage-gated sodium
channels.
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